Carbone, Michele


Michele Carbone is a board-certified anatomic pathology physician extensively engaged in mesothelioma research.

  • As center’s director, leads a multidisciplinary, international team of scientists in the study of mesothelioma.
  • Concentrating on unlocking how asbestos fibers and viruses work at the molecular level to become co-carcinogens in the transformation of human mesothelial cells into cancer cells.
  • Found that asbestos exposure triggers the secretion of HMGB1 and TNF-α that make mesothelial cells somewhat resistant to asbestos toxicity; asbestos-genetically damaged mesothelial cells may therefore survive and become cancer cells.
  • Clinical trial testing HMGB1 and TNF-α blockers.
  • Credited with identifying new biomarkers of early stage mesothelioma.
  • Discovered that families carrying germline mutations in the BAP1 gene have susceptibility to mesothelioma; now attempting to develop genetic testing for BAP1 mutations to identify individuals at high risk for mesothelioma.
  • Board director, American Cancer Society (2011).
  • Awarded Fogarty Fellowship from National Institutes of Health and 2008 INNOVATOR Award for International Collaboration in Cancer Research from Landon Foundation-American Association for Cancer Research; named a knight of the Republic of Italy.


  • M.D. degree from Medical School of Rome, Italy.
  • Ph.D. degree from Medical School of Rome, Italy